Results 21 to 30 of about 1,448,905 (180)
ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Amineh Ghaderi +9 more
doaj +1 more source
Disseminated fungal infection in a patient receiving zanubrutinib
Key Clinical Message We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second‐generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression‐related side effects.
Madalyn Walsh +3 more
doaj +1 more source
Supplemental material, sj-docx-1-msj-10.1177_13524585231192460 for Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor by Amit Bar-Or, Anne H Cross, Anthony
Elise E Drouin (16904347) +9 more
core +1 more source
Activated B-cell-like diffuse large B-cell lymphoma relies on B-cell receptor signaling to drive proliferation and survival. Downstream of the B-cell receptor, the key signaling kinases Bruton's tyrosine kinase and phosphoinositide 3-kinase δ offer ...
Anella Yahiaoui +9 more
doaj +1 more source
Chronic lymphocytic leukemia is a malignancy of mature auto-reactive B cells. Genetic and functional studies implicate B-cell receptor signaling as a pivotal pathway in its pathogenesis.
Adrian Wiestner
doaj +1 more source
Mechanism of Covalent Binding of Ibrutinib to Bruton’s Tyrosine Kinase revealed by QM/MM Calculations [PDF]
Ibrutinib is the first covalent inhibitor of Bruton’s tyrosine kinase (BTK) to be used in the treatment of B-cell cancers. Understanding the mechanism of covalent inhibition is crucial for the design of safer and more selective covalent inhibitors that ...
Angus, Voice +4 more
core +1 more source
Bruton’s tyrosine kinase (BTK) is a key protein from the TEC family and is involved in B-cell lymphoma occurrence and development. Targeting BTK is therefore an effective strategy for B-cell lymphoma treatment.
Xiangfan Yu +4 more
doaj +1 more source
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) [PDF]
International audienceRecent therapeutic advances for mantle cell lymphoma (MCL) include inhibitors of Bruton’s tyrosine kinase (BTK), a critical component in the B-cell receptor signaling pathway [1, 2].
Morschhauser, Franck +22 more
core +1 more source
Aberrant activation of Bruton’s tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematological malignancies.
Nan Hu (4067) +79 more
core +3 more sources
Sequence alignment of kinases. Table S2. Arthritis score and body weight during treatment period. Figure S1. Experimental design of collagen-induced arthritis. Figure S2. Effect of HM71224 on EGFR signaling. Figure S3. HM71224 inhibits Btk phosphorylation. Figure S4. HM71224 inhibits osteoclastogenesis. Figure S5.
Park, Jin +12 more
openaire +1 more source

